Skip to main content
This site is intended for US healthcare professionals only.

TAUVIDTM Frequently Asked Questions

Why am I having issues registering/signing in?

To access cases and assessments, you need to register first with:

  • First name
  • Last name
  • Email address
  • Password

We will add your first and last name to your Certificate of Completion. If you forget your password, we can send you a password reset email to your email address. View our privacy policy for more info on collecting and storing information.

What should I do if I received an email but don’t remember my password?

Click the “Forgot Your Password?” link, enter the email address that you registered with, and click the “Submit” button. You will receive an email with your password.

How long will the training take to complete?

On average, the online reader training program will take 3-4 hours to complete. You can stop and start it as you wish. The program will keep your place.

Which devices and browsers work with this training?

The TAUVID Reader Training site is a browser-based site that is compatible on desktop platforms. iPads and tablet devices are not supported, and the required software will not function correctly on these devices. Please review and complete the training on a laptop or desktop computer.

We recommend using Chrome or Safari browsers. Here is a link to all supported browsers:

Please note that the Internet Explorer (IE) browser is not supported.

Where can I find instructions on how to setup MIM software?

You can find step-by-step instructions for setting up MIM software on our MIM Setup page or download the user guide here.

Why does the MIMviewer close while trying to load a PET scan?

After multiple PET scan downloads, this has occurred with iPad devices. Consider switching to a different desktop device.

Why is it taking so long to load the PET scans?

This is usually a limitation of the device resources. Consider switching to a different device.

What type of certification do I receive for completing the TAUVID Online Reader Training Program?

A personalized Certificate of Completion will be given to healthcare professionals who complete the TAUVID Reader Training Program in its entirety. We’ll email the certification immediately after completion of the online training.

Do I receive CME credit for completing the TAUVID Reader Training Program?

No. This training is not accredited for CME.

Who can I contact if I have a question about this site or need technical support?

If you need assistance or technical support for the TAUVID Reader Training site, please call the Lilly Answers Center at 1-800-LillyRx (1-800-545-5979).

How can I get live support setting up or reading a TAUVID scan?

For live assistance from a member of the Lilly medical staff on scan setup or interpretation, please contact the Lilly Answers Center at 1-800-LillyRx (1-800-545-5979).

Indication

TAUVID is indicated for use with positron emission tomography (PET) imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD).


Limitations of Use
TAUVID is not indicated for use in the evaluation of patients for chronic traumatic encephalopathy (CTE).

  • TAUVID for intravenous use is supplied in multidose vials containing 300 MBq/mL to 3700 MBq/mL flortaucipir F 18.

Indication

TAUVID is indicated for use with positron emission tomography (PET) imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD).


Limitations of Use
TAUVID is not indicated for use in the evaluation of patients for chronic traumatic encephalopathy (CTE).

  • TAUVID for intravenous use is supplied in multidose vials containing 300 MBq/mL to 3700 MBq/mL flortaucipir F 18.

Important Safety Information

Risk of Misdiagnosis in Patients Evaluated for Alzheimers disease (AD)
TAUVID does not target β-amyloid, one of two required components of the neuropathological diagnosis of AD. TAUVID performance for detecting tau pathology was assessed in terminally ill patients, the majority of whom had AD dementia with B3 level neurofibrillary tangle (NFT) pathology. TAUVID performance for detecting tau pathology may be lower in patients in earlier stages of the pathological spectrum.

Negative TAUVID Scan
NFTs may be present at levels that qualify for the neuropathological diagnosis of AD (B2 tau pathology in the presence of at least moderate levels of cortical amyloid pathology) in patients with a negative TAUVID scan. Consider additional evaluation to confirm the absence of AD pathology in patients with a negative TAUVID scan.

False Positive TAUVID Scan
Small foci of noncontiguous tracer uptake may lead to a false positive TAUVID scan. Only uptake of tracer in the neocortex should contribute to the interpretation of a positive TAUVID scan.

Risk of Chronic Traumatic Encephalopathy Misdiagnosis
The safety and effectiveness of TAUVID have not been established for patients being evaluated for CTE. Preliminary non-clinical and clinical investigations suggest differences in tau conformation and distribution may limit flortaucipir F 18 binding. Therefore, TAUVID is not indicated for detection of CTE.

Radiation Risk
Diagnostic radiopharmaceuticals, including TAUVID, expose patients to radiation. Radiation exposure is associated with a dose-dependent increased risk of cancer. Ensure safe handling and preparation procedures to protect patients and health care workers from unintentional radiation exposure.

ADVERSE REACTIONS
The most common adverse reactions reported in clinical trials were headache (1.4%), injection site pain (1.2%), and increased blood pressure (0.8%).

USE IN SPECIAL POPULATIONSPregnancyAll radiopharmaceuticals, including TAUVID, have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of 
radiation dose. Advise a pregnant woman of the potential risks of fetal exposure to radiation doses with administration of TAUVID.

LactationAdvise a lactating woman to avoid breastfeeding for 4 hours after TAUVID administration in order to minimize radiation exposure to a breastfed infant.

Please see Full Prescribing Information for TAUVID.

FT HCP ISI 14SEP2022

Indication

TAUVID is indicated for use with positron emission tomography (PET) imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD).


Limitations of Use
TAUVID is not indicated for use in the evaluation of patients for chronic traumatic encephalopathy (CTE).

  • TAUVID for intravenous use is supplied in multidose vials containing 300 MBq/mL to 3700 MBq/mL flortaucipir F 18.

Important Safety Information

Risk of Misdiagnosis in Patients Evaluated for Alzheimers disease (AD)
TAUVID does not target β-amyloid, one of two required components of the neuropathological diagnosis of AD. TAUVID performance for detecting tau pathology was assessed in terminally ill patients, the majority of whom had AD dementia with B3 level neurofibrillary tangle (NFT) pathology. TAUVID performance for detecting tau pathology may be lower in patients in earlier stages of the pathological spectrum.

Negative TAUVID Scan
NFTs may be present at levels that qualify for the neuropathological diagnosis of AD (B2 tau pathology in the presence of at least moderate levels of cortical amyloid pathology) in patients with a negative TAUVID scan. Consider additional evaluation to confirm the absence of AD pathology in patients with a negative TAUVID scan.

False Positive TAUVID Scan
Small foci of noncontiguous tracer uptake may lead to a false positive TAUVID scan. Only uptake of tracer in the neocortex should contribute to the interpretation of a positive TAUVID scan.

Risk of Chronic Traumatic Encephalopathy Misdiagnosis
The safety and effectiveness of TAUVID have not been established for patients being evaluated for CTE. Preliminary non-clinical and clinical investigations suggest differences in tau conformation and distribution may limit flortaucipir F 18 binding. Therefore, TAUVID is not indicated for detection of CTE.

Radiation Risk
Diagnostic radiopharmaceuticals, including TAUVID, expose patients to radiation. Radiation exposure is associated with a dose-dependent increased risk of cancer. Ensure safe handling and preparation procedures to protect patients and health care workers from unintentional radiation exposure.

ADVERSE REACTIONS
The most common adverse reactions reported in clinical trials were headache (1.4%), injection site pain (1.2%), and increased blood pressure (0.8%).

USE IN SPECIAL POPULATIONSPregnancyAll radiopharmaceuticals, including TAUVID, have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of 
radiation dose. Advise a pregnant woman of the potential risks of fetal exposure to radiation doses with administration of TAUVID.

LactationAdvise a lactating woman to avoid breastfeeding for 4 hours after TAUVID administration in order to minimize radiation exposure to a breastfed infant.

Please see Full Prescribing Information for TAUVID.

FT HCP ISI 14SEP2022

Indication

TAUVID is indicated for use with positron emission tomography (PET) imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD).


Limitations of Use
TAUVID is not indicated for use in the evaluation of patients for chronic traumatic encephalopathy (CTE).

  • TAUVID for intravenous use is supplied in multidose vials containing 300 MBq/mL to 3700 MBq/mL flortaucipir F 18.